Loading...
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
BACKGROUND: In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was...
Na minha lista:
| Udgivet i: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5598064/ https://ncbi.nlm.nih.gov/pubmed/28903775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0595-6 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|